A nanozyme-enabled colorimetric liquid biopsy platform for monitoring treatment response and recurrence in colorectal cancer

Faculty Mentor

Dr. Gang Chen

Location

Russell Union Ballroom

Type of Research

On-going

Session Format

Poster Presentation

College

College of Science & Mathematics

Department

Biochemistry, Chemistry, and Physics

Abstract

Colorectal cancer (CRC) patient management relies heavily on longitudinal monitoring of treatment response and disease recurrence. Blood-based biomarkers offer a minimally invasive approach for surveillance; however, existing assays, most notably enzyme- linked immunosorbent assays (ELISAs) for carcinoembryonic antigen (CEA) and CA19-9, are constrained by enzymatic instability, matrix interference, batch variability, and cost. These limitations restrict scalability and reduce suitability for frequent monitoring in real-world clinical settings. There is a pressing need for sensitive, robust, and low-cost diagnostic platforms that perform reliably in complex biological matrices such as human plasma. Peroxidase (POD)-like nanozymes are attractive alternatives to natural enzymes due to their superior physicochemical stability and tunable catalytic properties. Among them, Au@Pt core- shell nanozymes provide a uniquely engineerable platform in which Pt catalytic activity can be systematically modulated through control of shell thickness, crystallographic facets, and surface chemistry. In this project we are establishing the technical and translational feasibility of an antibody-guided, Au@Pt nanozyme-enabled colorimetric liquid biopsy platform for CRC biomarker monitoring.

Program Description

.

Start Date

4-23-2026 2:00 PM

End Date

4-23-2026 4:00 PM

This document is currently not available here.

Share

COinS
 
Apr 23rd, 2:00 PM Apr 23rd, 4:00 PM

A nanozyme-enabled colorimetric liquid biopsy platform for monitoring treatment response and recurrence in colorectal cancer

Russell Union Ballroom

Colorectal cancer (CRC) patient management relies heavily on longitudinal monitoring of treatment response and disease recurrence. Blood-based biomarkers offer a minimally invasive approach for surveillance; however, existing assays, most notably enzyme- linked immunosorbent assays (ELISAs) for carcinoembryonic antigen (CEA) and CA19-9, are constrained by enzymatic instability, matrix interference, batch variability, and cost. These limitations restrict scalability and reduce suitability for frequent monitoring in real-world clinical settings. There is a pressing need for sensitive, robust, and low-cost diagnostic platforms that perform reliably in complex biological matrices such as human plasma. Peroxidase (POD)-like nanozymes are attractive alternatives to natural enzymes due to their superior physicochemical stability and tunable catalytic properties. Among them, Au@Pt core- shell nanozymes provide a uniquely engineerable platform in which Pt catalytic activity can be systematically modulated through control of shell thickness, crystallographic facets, and surface chemistry. In this project we are establishing the technical and translational feasibility of an antibody-guided, Au@Pt nanozyme-enabled colorimetric liquid biopsy platform for CRC biomarker monitoring.